BACE1 Specific Neutra™ Antibody Products
Product listBeta-secretase 1 (BACE1), also known as β-secretase, is a type I transmembrane protease. BACE1 cleaves the membrane-bound APP at the N-terminus to extracellularly release the soluble APP. BACE1 is associated with Alzheimer's Disease (AD) and Myositis.
Its Gene ID: 23621, UniProtKB ID: P56817, and OMIM ID: 604252.
Defective Signaling Pathways of BACE1
To study the molecular basis of BACE1-associated pathological generation and progression of AD, we focused on the defective signaling pathways of BACE1.
- BACE1 promotes the production of insoluble Aβ isoforms.
- NF-κB activation increases BACE1 expression, Aβ production, and downstream signaling pathways.
- GSK3β triggers the activation of NF-κ, sequential BACE1 expression and Aβ production.
Fig.1 BACE1 associated defective signaling pathways.1
Therapeutic Strategies for BACE1
BACE1 activity is a key factor for the pathogenesis of AD, which highlights the potential of BACE1 as a promising target for the diagnosis and treatment research of AD. The BACE1-related strategies are listed below:
- The concentration level and the enzymatic activity of BACE1 could be monitored as biomarkers for the treatments of AD by targeting BACE1.
- Small-molecule inhibitors of BACE1 (see in Tab. 1) could be developed to lower the insoluble Aβ levels.
Tab. 1 Current BACE1 inhibitors targeting Aβ reduction.2
- BACE1-based bispecific antibodies or nanobodies that could penetrate the blood-brain barrier may alleviate the dysfunction and progression of AD pathology. As shown in Fig.2, the transferrin-BACE1 bispecific antibody guarantees higher antibody working concentrations in the brain and enhanced therapeutic responses.
Fig.2 BACE1 associated defective signaling pathways.3
Creative Biolabs offers various anti-BACE1 antibodies for research in neuroscience and oncology. These antibodies could be used in applications such as immunoassays, blocking and neutralization. We also offer a customized service for the development of BACE1-based bispecific antibodies and nanobodies.
REFERENCES
- Bazzari, Firas H., and Amjad H. Bazzari. "BACE1 Inhibitors for Alzheimer's Disease: The Past, Present and Any Future?." Molecules 27.24 (2022): 8823.
- Das, Brati, and Riqiang Yan. "A close look at BACE1 inhibitors for Alzheimer's disease treatment." CNS drugs 33.3 (2019): 251-263.
- Paul, Steven M. "Therapeutic antibodies for brain disorders." Science translational medicine 3.84 (2011): 84ps20-84ps20.
